GlassScriptPhysician profile
Warren J Plauche
NPI 1528195765
$1,784.60
in general payments reported to CMS, 2019-2025
16 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.73 · 2020: $32.53 · 2021: $114 · 2022: $342 · 2023: $630 · 2024: $391 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $901.29 | 2019-2025 | Nuplazid |
| Avanir Pharmaceuticals, INC. | $165.50 | 2019-2022 | |
| Boston Scientific Corporation | $158.92 | 2021-2025 | General - Vascular Intervention |
| Abbvie INC. | $148.54 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $123.78 | 2023-2024 | Nuedexta, Rexulti |
| Sumitomo Pharma America, INC. | $51.89 | 2023 | Aptiom |
| Astellas Pharma US INC | $40.12 | 2022-2023 | Veozah |
| Lilly USA, LLC | $28.26 | 2022-2023 | Mounjaro, Trulicity |
| Lundbeck LLC | $25.04 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $23.60 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $22.81 | 2023 | Austedo Xr |
| Urovant Sciences INC | $21.51 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.03 | 2025 | Caplyta |
| Ardelyx, INC. | $19.01 | 2024 | Ibsrela |
| Neurocrine Biosciences, INC. | $18.91 | 2024 | Ingrezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Plauche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.